MA34642B1 - Anticorps dirigé contre le tweak humain et leurs utilisations - Google Patents
Anticorps dirigé contre le tweak humain et leurs utilisationsInfo
- Publication number
- MA34642B1 MA34642B1 MA35867A MA35867A MA34642B1 MA 34642 B1 MA34642 B1 MA 34642B1 MA 35867 A MA35867 A MA 35867A MA 35867 A MA35867 A MA 35867A MA 34642 B1 MA34642 B1 MA 34642B1
- Authority
- MA
- Morocco
- Prior art keywords
- tweak
- diseases
- directed against
- antibodies directed
- against human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Plant Pathology (AREA)
Abstract
L'invention concerne un anticorps se liant à TWEAK, caractérisé par la liaison à TWEAK, caractérisé en ce qu'il comprend en tant que domaine variable de la chaîne lourde un CDR3H choisi dans le groupe consistant en SEQ ID NO: 8, 16 ou 24, qui est utile pour le traitement du cancer ou de maladies auto-immunes, de la polyarthrite rhumatoïde, de la polyarthrite psoriasique, de maladies musculaires, par exemple la dystrophie musculaire, de la sclérose en plaque, de maladies rénales chroniques, de maladies osseuses, par exemple la dégénérescence osseuse dans des myélomes multiples, du lupus érythémateux disséminé, de la néphropathie lupique et de lésions vasculaires.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10186536 | 2010-10-05 | ||
PCT/EP2011/067070 WO2012045671A1 (fr) | 2010-10-05 | 2011-09-30 | Anticorps dirigé contre le tweak humain et leurs utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
MA34642B1 true MA34642B1 (fr) | 2013-11-02 |
Family
ID=43086385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA35867A MA34642B1 (fr) | 2010-10-05 | 2013-05-03 | Anticorps dirigé contre le tweak humain et leurs utilisations |
Country Status (21)
Country | Link |
---|---|
US (1) | US9187564B2 (fr) |
EP (1) | EP2625200A1 (fr) |
JP (1) | JP5941049B2 (fr) |
KR (1) | KR101584416B1 (fr) |
CN (1) | CN103154029B (fr) |
AR (1) | AR083336A1 (fr) |
AU (1) | AU2011311673B2 (fr) |
BR (1) | BR112013007293A2 (fr) |
CA (1) | CA2809632A1 (fr) |
CL (1) | CL2013000901A1 (fr) |
CR (1) | CR20130108A (fr) |
EA (1) | EA201300418A1 (fr) |
EC (1) | ECSP13012542A (fr) |
HK (1) | HK1186195A1 (fr) |
MA (1) | MA34642B1 (fr) |
MX (1) | MX343114B (fr) |
NZ (1) | NZ607588A (fr) |
PE (1) | PE20131411A1 (fr) |
SG (1) | SG188605A1 (fr) |
TW (1) | TWI482630B (fr) |
WO (1) | WO2012045671A1 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5550799B2 (ja) * | 1999-01-15 | 2014-07-16 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Tweakのアンタゴニストおよびtweakレセプターのアンタゴニスト、ならびに免疫学的障害を処置するためのこれらの使用 |
CN102793921A (zh) | 2002-04-09 | 2012-11-28 | 比奥根艾迪克Ma公司 | 用于治疗tweak 相关病症的方法 |
EP2332408B1 (fr) | 2005-02-17 | 2013-11-13 | Biogen Idec MA Inc. | Traitement de troubles neurologiques |
ES2432564T3 (es) | 2005-05-10 | 2013-12-04 | Biogen Idec Ma Inc. | Tratamiento y evaluación de trastornos inflamatorios |
WO2006138219A2 (fr) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Procedes d'evaluation de patients |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
CA2824824A1 (fr) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Proteines monovalentes de liaison a l'antigene |
MX341921B (es) | 2011-02-28 | 2016-09-07 | Hoffmann La Roche | Proteinas de union a antigeno. |
AU2013244999A1 (en) | 2012-04-05 | 2014-09-25 | F. Hoffmann-La Roche Ag | Bispecific antibodies against human TWEAK and human IL17 and uses thereof |
JP2016000003A (ja) * | 2013-04-19 | 2016-01-07 | アステラス製薬株式会社 | 新規抗ヒトtweak抗体 |
WO2015051234A2 (fr) * | 2013-10-04 | 2015-04-09 | Biogen Idec Ma Inc. | Antagonistes de tweak pour traiter la néphropathie lupique et l'atrophie musculaire |
EP3174897B1 (fr) * | 2014-07-29 | 2020-02-12 | F.Hoffmann-La Roche Ag | Anticorps multi-spécifiques |
CN112180100A (zh) * | 2020-09-27 | 2021-01-05 | 西安交通大学 | Tweak作为鉴别不同类型银屑病的分子标志物的应用 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0307434B2 (fr) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Anticorps alteres |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
JP3537535B2 (ja) | 1994-07-14 | 2004-06-14 | 株式会社中埜酢店 | 免疫グロブリンg結合糖鎖構造に基づく臨床検査方法 |
AU7668696A (en) | 1995-11-03 | 1997-05-22 | Austin Research Institute, The | Methods and compositions for the reduction of xenotransplantation rejection |
DE69734397T2 (de) | 1996-08-07 | 2006-07-06 | Biogen Idec Ma Inc., Cambridge | Tumor-nekrose-faktor ähnliches ligand |
WO1998033523A1 (fr) | 1997-01-31 | 1998-08-06 | Biovation Limited | Procede et molecules de vaccination |
ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
BRPI9910332B8 (pt) | 1998-05-06 | 2021-05-25 | Genentech Inc | método para purificação de um polipeptídio a partir de uma composição |
EP1051432B1 (fr) | 1998-12-08 | 2007-01-24 | Biovation Limited | Modification de l'immunogenicite de proteines |
JP5550799B2 (ja) | 1999-01-15 | 2014-07-16 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Tweakのアンタゴニストおよびtweakレセプターのアンタゴニスト、ならびに免疫学的障害を処置するためのこれらの使用 |
CN102793921A (zh) | 2002-04-09 | 2012-11-28 | 比奥根艾迪克Ma公司 | 用于治疗tweak 相关病症的方法 |
AU2004242846A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
US7109304B2 (en) | 2003-07-31 | 2006-09-19 | Immunomedics, Inc. | Humanized anti-CD19 antibodies |
AR045614A1 (es) | 2003-09-10 | 2005-11-02 | Hoffmann La Roche | Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos |
WO2006052926A2 (fr) | 2004-11-08 | 2006-05-18 | University Of Maryland, Baltimore | Tweak comme cible therapeutique permettant de traiter les maladies du systeme nerveux central associees a un oedeme cerebral et a une mort cellulaire |
CN105535967B (zh) | 2005-02-15 | 2022-05-03 | 杜克大学 | 抗cd19抗体及其在肿瘤学中的应用 |
EP2332408B1 (fr) | 2005-02-17 | 2013-11-13 | Biogen Idec MA Inc. | Traitement de troubles neurologiques |
US20090068102A1 (en) | 2005-02-17 | 2009-03-12 | Biogen Idec Ma Inc. | Treating stroke |
CN102225200A (zh) | 2005-03-07 | 2011-10-26 | 健泰科生物技术公司 | 用于调控tweak和fn14活性的方法和组合物 |
TW200720289A (en) | 2005-04-01 | 2007-06-01 | Hoffmann La Roche | Antibodies against CCR5 and uses thereof |
ES2432564T3 (es) | 2005-05-10 | 2013-12-04 | Biogen Idec Ma Inc. | Tratamiento y evaluación de trastornos inflamatorios |
ES2507069T3 (es) | 2005-05-27 | 2014-10-14 | Biogen Idec Ma Inc. | Anticuerpos de unión a TWEAK |
WO2006130429A2 (fr) | 2005-05-27 | 2006-12-07 | Biogen Idec Ma Inc. | Traitement du cancer |
EP1904101A4 (fr) | 2005-06-08 | 2011-06-15 | Univ Duke | Therapie a anticorps diriges contre cd19 a des fins de transplantation |
US8097703B2 (en) | 2005-06-20 | 2012-01-17 | Medarex, Inc. | CD19 antibodies and their uses |
CA2619825A1 (fr) | 2005-08-19 | 2007-03-01 | Centocor, Inc. | Preparations d'anticorps resistants a la proteolyse |
PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
DE102005060813A1 (de) | 2005-12-20 | 2007-06-28 | Rheinisch-Westfälische Technische Hochschule Aachen | Selektive Markierung der Glykane von Antikörpern mit modifizierten Nukleotidzuckern als Substrate von rekombinanten Galactosyltransferasen |
EP1878747A1 (fr) | 2006-07-11 | 2008-01-16 | greenovation Biotech GmbH | Anticorps glyco-modifiés |
AU2007317755A1 (en) | 2006-10-27 | 2008-05-15 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
US8093006B2 (en) | 2009-04-02 | 2012-01-10 | Hoffmann-La Roche Inc. | Antibodies against human tweak and uses thereof |
-
2011
- 2011-09-30 EA EA201300418A patent/EA201300418A1/ru unknown
- 2011-09-30 US US13/250,485 patent/US9187564B2/en not_active Expired - Fee Related
- 2011-09-30 MX MX2013003592A patent/MX343114B/es active IP Right Grant
- 2011-09-30 CA CA2809632A patent/CA2809632A1/fr not_active Abandoned
- 2011-09-30 BR BR112013007293A patent/BR112013007293A2/pt not_active IP Right Cessation
- 2011-09-30 PE PE2013000786A patent/PE20131411A1/es not_active Application Discontinuation
- 2011-09-30 EP EP11766965.5A patent/EP2625200A1/fr not_active Withdrawn
- 2011-09-30 WO PCT/EP2011/067070 patent/WO2012045671A1/fr active Application Filing
- 2011-09-30 SG SG2013020318A patent/SG188605A1/en unknown
- 2011-09-30 JP JP2013532140A patent/JP5941049B2/ja not_active Expired - Fee Related
- 2011-09-30 KR KR1020137011352A patent/KR101584416B1/ko not_active IP Right Cessation
- 2011-09-30 AU AU2011311673A patent/AU2011311673B2/en not_active Ceased
- 2011-09-30 CN CN201180047922.2A patent/CN103154029B/zh not_active Expired - Fee Related
- 2011-10-03 AR ARP110103661A patent/AR083336A1/es unknown
- 2011-10-04 TW TW100135935A patent/TWI482630B/zh not_active IP Right Cessation
-
2012
- 2012-12-24 NZ NZ607588A patent/NZ607588A/en not_active IP Right Cessation
-
2013
- 2013-03-12 CR CR20130108A patent/CR20130108A/es unknown
- 2013-04-04 EC ECSP13012542 patent/ECSP13012542A/es unknown
- 2013-04-04 CL CL2013000901A patent/CL2013000901A1/es unknown
- 2013-05-03 MA MA35867A patent/MA34642B1/fr unknown
- 2013-12-10 HK HK13113725.0A patent/HK1186195A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP2013543383A (ja) | 2013-12-05 |
WO2012045671A1 (fr) | 2012-04-12 |
US20120121583A1 (en) | 2012-05-17 |
EP2625200A1 (fr) | 2013-08-14 |
AU2011311673B2 (en) | 2015-09-17 |
JP5941049B2 (ja) | 2016-06-29 |
TWI482630B (zh) | 2015-05-01 |
MX2013003592A (es) | 2013-05-31 |
AR083336A1 (es) | 2013-02-21 |
TW201219054A (en) | 2012-05-16 |
EA201300418A1 (ru) | 2013-09-30 |
SG188605A1 (en) | 2013-04-30 |
CA2809632A1 (fr) | 2012-04-12 |
HK1186195A1 (zh) | 2014-03-07 |
KR20130062369A (ko) | 2013-06-12 |
ECSP13012542A (es) | 2013-06-28 |
CL2013000901A1 (es) | 2013-11-29 |
NZ607588A (en) | 2014-02-28 |
US9187564B2 (en) | 2015-11-17 |
CN103154029B (zh) | 2015-11-25 |
BR112013007293A2 (pt) | 2016-06-14 |
KR101584416B1 (ko) | 2016-01-13 |
CN103154029A (zh) | 2013-06-12 |
PE20131411A1 (es) | 2013-12-16 |
CR20130108A (es) | 2013-04-29 |
MX343114B (es) | 2016-10-25 |
AU2011311673A1 (en) | 2013-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA34642B1 (fr) | Anticorps dirigé contre le tweak humain et leurs utilisations | |
LUC00053I2 (fr) | Anticorps diriges contre cd38 pour le traitement du myelome multiple | |
MX2009006891A (es) | Anticuerpos cd44. | |
MA35659B1 (fr) | Protéine de liaison à un antigène et son utilisation comme produit d'adressage pour le traitement du cancer | |
MA33402B1 (fr) | Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps | |
MA42542B1 (fr) | Molécules se liant à pd-1 et méthodes d'utilisation correspondantes | |
MA38194A1 (fr) | Anticorps anti-ceacam5 et leurs utilisations | |
EA200901263A1 (ru) | Конденсированный аминопиридин в качестве ингибиторов hsp90 | |
MX2010010387A (es) | Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos. | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
WO2009048537A3 (fr) | Anticorps humanisé | |
MX2009009194A (es) | Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes. | |
MA35174B1 (fr) | Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines | |
MA31308B1 (fr) | Anticorps antisclerostine. | |
MA34175B1 (fr) | Anticorps anti-cxcr4 humanisés pour le traitement de cancer | |
MA30318B1 (fr) | Composes de sulfonamide de pyrimidinyle inhibant l'adhesion leucocytaire mediee par vla-4 | |
UA116614C2 (uk) | Антитіло до фактора d і його застосування | |
TW200740844A (en) | Novel MAdCAM antibodies | |
TW200738748A (en) | Human monoclonal antibody human CD134 (OX40) and methods of making and using same | |
EA201000424A1 (ru) | Антитела к il-23 | |
MA32928B1 (fr) | Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer | |
MA33387B1 (fr) | Polypeptides et procede de traitement | |
MA37946A1 (fr) | Traitement de la polyarthrite rhumatoïde | |
MA30876B1 (fr) | Anticorps de la lymphotoxine-alpha | |
EA201892184A1 (ru) | Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора |